amrinone has been researched along with Constriction, Pathological in 1 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tateyama, T | 1 |
| Suzuki, H | 1 |
| Fukuyama, H | 1 |
| Fujiwara, R | 1 |
| Abe, Y | 1 |
| Okutsu, Y | 1 |
1 other study available for amrinone and Constriction, Pathological
| Article | Year |
|---|---|
[Amrinone (50 micrograms.kg-1.min-1) does not impair regional myocardial tissue metabolism during the 40%-decrease of left anterior descending coronary flow].
Topics: Amrinone; Animals; Cardiotonic Agents; Constriction, Pathologic; Coronary Circulation; Coronary Dise | 1996 |